Prof. Dr.
Coşkun TECİMER

Prof. Dr.
Coşkun TECİMER

Randevu Al
İstanbul Florence Nightingale Hastanesi
Gayrettepe Florence Nightingale Hastanesi
    • 2006

      Demiroğlu Bilim Üniversitesi
      Tıbbi Onkoloji Bilim Dalı Başkanı

      2006
      Demiroğlu Bilim Üniversitesi
      İç Hastalıkları Anabilim Dalında Profesör

      2006
      Demiroğlu Bilim Üniversitesi
      Tıbbi Onkoloji Bilim Dalı Başkanlığı

      2000
      Kadir Has Üniversitesi Tıp Fakültesi
      İç Hastalıkları, Profesör

      2000 - 2004
      Kadir Has Üniversitesi Tıp Fakültesi
      İç Hastalıkları Anabilim Dalında Profesör

      1999
      Marmara ve Louisville Üniversiteleri
      Tıbbi Onkoloji Uzmanı

      1999
      Marmara ve Louisville Üniversiteleri
      Hematoloji Uzmanı

      1996 - 1999
      ABD’de Louisville Üniveritesi James Graham Kanser Merkezi
      Hematoloji/Onkoloji Bölümünde fellow

      1994 - 1996
      Marmara Üniversitesi Tıp Fakültesi
      Hematoloji Bilim Dalında fellow

      1993
      İnönü Üniversitesi Tıp Fakültesi
      İç Hastalıkları, Doçent

      1993 - 1994
      İnönü Üniversitesi Tıp Fakültesi
      İç Hastalıkları Anabilim Dalında Doçent

      1991 - 1993
      İnönü Üniversitesi Tıp Fakültesi
      İç Hastalıkları Anabilim Dalı Başkanı, Dahili Tıp Bilimleri Bölüm Başkan Vekilliği

      1991 - 1993
      İnönü Üniversitesi Tıp Fakültesi
      Dönem 4 Koordinatörlüğü

      • Tıbbi Onkoloji Derneği
      • Türk Onkoloji Grubu Derneği
      • Türk Hematoloji Derneği
      •  American Society of Clinical Oncology
      •  American Society of Hematology
      •  European Society of Medical Oncology
      •  Akciğer Kanseri Derneği
      •  Türk Tabipleri Birliği İstanbul Tabip Odası

  • Uluslararası Hakemli Dergilerde Yayımlanan Makaleler

      • 1- Tecimer C, Oram Y, Tecimer T. Lupus vulgaris in a patient with pulmonary tuberculosis. Cutis 1994; 53:246-8.
      • 2- Tecimer C, Yam LT. Surreptitious superwarfarin poisoning with brodifacoum. Southern  Medical Journal 1997; 90:1053-5. 
      • 3- Tecimer C, Loy BA, Martin AW. Acute myeloblastic leukemia (M0) with an unusual chromosomal abnormality: Translocation (1;14) (p13;q32). Cancer Genetics and Cytogenetics 1999; 111:175-7.
      • 4- Tecimer C, Doering D, Abdulhay G, Goldsmith J, Meyer JS, Wittliff JL.  Clinical    relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in ovarian cancer. International Journal of Gynecological Cancer 2000; 10:372-81.
      • 5- Tecimer C, Doering D, Abdulhay G, Goldsmith J, Meyer JS, Wittliff JL.  Clinical relevance of urokinase-type plasminogen activator, its receptor and inhibitor type 1 in endometrial cancer. Gynecologic Oncology 2001; 80:48-55.
      • 6- Alço G, İğdem Ş, Dinçer M, Tecimer C, Şentürk R, Vural M, Okkan S.    Gemcitabine induced radiation recall myositis: Report of two cases. International Journal of Hematology and Oncology 2009; 19: 249-253. 
      • 7- Akun E, Okutur K, Seber S, Korkmaz T, Aydın K, Bozkurt M, Namal E, Hasbal B, Tecimer C, Demir G. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer. Journal of Balkan Union of Oncology 2012; 17: 669-76.  
      • 8- Ordu Ç, Pilancı KN, Köksal Üİ, Okutur K, Sağlam S, Tecimer C, Demir G. Can megestrol acetate induce thrombosis in advanced oncology patients receiving chemotherapy? Asian Pacific Journal of Cancer Prevention 2014; 15: 10165-9.
      • 9- Ordu Ç, Pilancı KN, Avcı N, Yıldız İ, Demirhan Ö, Alço G, Köksal Üİ, Elbüken F, Sağlam S, Tecimer C, Demir G. Prognostic relevance of sunitinib toxicities and comparison of continuous vs intermittent sunitinib dosing schedule in metastatic renal cell cancer patients. Contemporary Oncology 2016; 20 (2).
      • 10-Okutur K, Başsülü N, Dalar L, Aydın K, Bozkurt M, Pilancı KN, Doğusoy GB, Tecimer C, Mandel NM, Demir G. Predictive and prognostic significance of p27, Akt, PTEN and PI3K expression in HER2-positive metastatic breast cancer. Asian Pacific Journal of Cancer Prevention 2015; 16: 2645-51.
      • 11-Pilancı KN, Alço G, Ordu Ç, Sarsenov D, Çelebi F, Erdoğan Z, Ağaçayak F, İlgün S, Tecimer C, Demir G, Eralp Y, Okkan S, Özmen V. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment? Medicine 2015; 94: e671.  
      • 12- Pilancı KN, Elüken F, Ordu Ç, Köksal G, Tekelioğlu MH, Okutur K, Göksel S, Köksal Ü, Alçal T, Tecimer C. A rare case of sunitinib-induced hyperammonemic encephalopathy and hypothyroidism in metastatic renal cell carcinoma. Am J Ther 2016; 23(2).
      • 13- Alço G, İğdem S, Dinçer M, Özmen V, Sağlam S, Selamoğlu D, Erdoğan Z, Ordu C, Pilancı KN, Bozdoğan A, Yenice S, Tecimer C, Demir G, Köksal G, Okkan S. Vitamin D levels in patients with breast cancer: importance of dressing style. Asian Pac J Cancer Prev 2014; 15: 1357-62.
      • 14- Tavukçu HH, Aytaç O, Aktepe F, Atuğ F, Erdem L, Tecimer C. Ductal adenocarcinoma  of the prostate with a rare clinical presentation: late gastric metastasis. Tavukçu HH, Aytaç O, Aktepe F, Atuğ F, Erdem L, Tecimer C. Urol Case Rep 2016; 7: 28-30.             
      • Uluslararası Bilimsel Toplantılarda Sunulan ve Bildiri Kitabında Basılan Bildiriler
      •  1- Oto A, Tecimer C, Oram E, Uğurlu Ş, Karamehmetoğlu A, Oram A. Disturbance in the    autonomic control of the heart rate in patients with acute myocardial infarction. Mediterranean Association of Cardiology and Cardiac Surgery 1st Annual Meeting, Cavtat-Dubrovnic Yugoslavia, October 8-11, 1987. Abstracts, 199.
      • 2- Alpdoğan O, Budak-Alpdoğan T, Tanrıverdi S, Tecimer C, Fıratlı-Tuğlular T, Bayık M,  Akoğlu T. The efficacy of mega-dose methylprednisolon treatment in patients with idiopathic thrombocytopenic purpura. The 13th Meeting of the International Society of Haematology (European and African Division), İstanbul, September 3-8, 1995. Abstract Book, Abstract No: 697.
      • 3- Tecimer C, Bhupalam L, Djulbegovic B. Is standard heparin superior to low molecular weight heparin in malignancy related deep vein thrombosis? The 39th Annual Meeting of the American Society of Hematology, San Diego, CA, December 5-9, 1997. Blood 1997; 90: 124b.
      • 4- Wittliff JL, Smolenkov AS, Tecimer C, Schmitt GA, Tuckson WB, Galandiuk S. 
      •      Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR)   and its inhibitor (PAI-1) in Russian and American patients with colon carcinoma. The Meeting of the Clinical Ligand Assay Society, New York, NY, Spring 1998. J Clin Ligand Assay 1998; 21: 87.
      • 5- Tecimer C, Doering DL, Meyer JS, Abdulhay G, Goldsmith LJ, Wittliff JL. Prognostic significance of uPA, uPAR and PAI-1 expression in the management of endometrial cancer. The 35th Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, May 15-18, 1999. Proceedings 1999; 18: 160a.  
      • 6- Dane F, Yumuk PF, Turhal NS, Ekenel M, Başaran G, İyikesici MS, Tecimer C. FOLFOX 4 in metastatic colorectal cancer (MCRC) patients who progressed after infusional 
      • 5-FU/irinotecan based combination regimens.  The 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004. J Clin Onc, 2004; 22: 301S. 
      • 7- İğdem Ş, Altın M, Alço G, Ercan T, Kara B, Ünalan B, Tecimer C, Köksal G,  Turkan S, Okkan S. PET/CT guided, dose painting IMRT for nasopharyngeal carcinoma. Proceedings of the American Society for Therapeutic Radiology and Oncology 50th Meeting, 21-25 September, 2008 Boston, MA. Radiation Oncology Biology, Physics 2008; 72: S424-5.
      • 8- Okutur K, Turan C, Tecimer C, Demir G. Toxicity of bevacizumab (BV) in metastatic colorectal cancer (MCRC): Data from clinical practice. 7th Congress of B.U.O.N., 16-19 October, 2008, İzmir, Turkey. Journal of B.U.O.N. 2008; 13 (Suppl 1):  S31.
      • 9- Okutur K, Demir G, Tecimer C, Erdem L, Turan C. Toxicity of bevacizumab in metastatic colorectal cancer: Data from clinical practice. Poster presentation. 18th International Postgraduate Course of the International Association of Surgeons and Gastroenterologists and Oncologists, October 2008. Hepatogastroenterology Current Medical and Surgical Trends 2008; 55 (Suppl 1): S165-6.
      • 10- Okutur K, Aydın K, Bozkurt M, Turan C, Demir N, Hasbal B, Erdem L, Tecimer C, Demir G. Toxicity of bevacizumab in metastatic colorectal cancer: Data from clinical practice. 1st Congress of the Mediterranean Multidisciplinary Oncology Forum, 10-13 September 2009, Athens. Abstract 28.
      • 11- İğdem Ş, Altın M, Alço G, Ercan T, Ünalan B, Tecimer C, Köksal G, Gürses K, Demir G, Okkan S. Whole field simultaneous integrated boost IMRT in nasopharyngeal cancer. I J Radiation Oncology Biology Physics 2010; 78: S478.
      • 12- Başaran G, Sağlam S, Tansan S, Demirel M, Gökmen E, Aktan S, Göker E, Kaban KK, Saip P, Demir G, Bavbek SE, Mandel NM, Tecimer C, Turhal NS, Garipoğlu M. The impact of 21-gene recurrence score (RS) scores on treatment decisions. Retrospective evaluation in Turkish early-stage breast cance (BC) patients.  The 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011. J Clin Onc, 2011; 29: Abstract No:e11042.
      • 13- Bozkurt M, Okutur K, Aydın K, Namal E, Öztürk A, Tecimer C, Akçalı Z, Demir G. The impact of early thromboembolic event on prognosis in cancer parients: A single-center analysis of 1838 patients. The 47th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2011. J Clin Onc, 2011; 29: Abstract No:e19694.
      • 14- Pilancı KN, Ordu Ç, Okutur K, İner Koksal Ü, Sağlam S, Tecimer C, Demir G. 17. European Cancer Congress, Amsterdam, 27 September-1 October 2013.
      • 15- Alço G, İğdem Ş, Dinçer M, Özmen V, Demir G, Köksal G, Tecimer C, Selamoğlu D, Pilancı KN, Okkan S. Can megestrol acetate induce thrombosis in oncology patients? 17. European Cancer Congress, Amsterdam, 27 September-1 October 2013.  
      •        
      •